Search
Longeveron Inc
LGVNAdd to Watchlist
2.600USD
0.0000.00%
Market hours 09/23, 15:34（ET）
82.16MMarket Cap
LossP/E TTM
About Longeveron Inc Company
Longeveron Inc. is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action, encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. The Company is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B development programs have received five distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.
Longeveron Inc Profile
Ticker SymbolLGVN
Company nameLongeveron Inc
IPO dateFeb 12, 2021
CEOPowell (Than)
Number of employees25
Security typeOrdinary Share
Fiscal year-endFeb 12
Address1951 NW 7th Ave
CityMIAMI
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code33136
Phone13053027158
Websitehttps://www.longeveron.com/
Ticker SymbolLGVN
IPO dateFeb 12, 2021
CEOPowell (Than)
Company Executives of Longeveron Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Nataliya Agafonova, M.D.
Dr. Nataliya Agafonova, M.D.
Chief Medical Officer
Chief Medical Officer
60.64K
+47.17%
Dr. Nataliya Agafonova, M.D.
Dr. Nataliya Agafonova, M.D.
Chief Medical Officer
Chief Medical Officer
60.64K
+47.17%
Dr. Nataliya Agafonova, M.D.
Dr. Nataliya Agafonova, M.D.
Chief Medical Officer
Chief Medical Officer
60.64K
+47.17%
Mr. Stephen H. (Steve) Willard, Esq.
Mr. Stephen H. (Steve) Willard, Esq.
Chief Executive Officer
Chief Executive Officer
58.42K
-3.09%
Mr. Stephen H. (Steve) Willard, Esq.
Mr. Stephen H. (Steve) Willard, Esq.
Chief Executive Officer
Chief Executive Officer
58.42K
-3.09%
Mr. Stephen H. (Steve) Willard, Esq.
Mr. Stephen H. (Steve) Willard, Esq.
Chief Executive Officer
Chief Executive Officer
58.42K
-3.09%
Mr. Devin Blass
Mr. Devin Blass
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
57.23K
+49.97%
Mr. Devin Blass
Mr. Devin Blass
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
57.23K
+49.97%
Mr. Devin Blass
Mr. Devin Blass
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
57.23K
+49.97%
Dr. Joshua M. Hare, M.D.
Dr. Joshua M. Hare, M.D.
Executive Chairman of the Board, Co-Founder, Chief Science Officer
Executive Chairman of the Board, Co-Founder, Chief Science Officer
54.25K
+52.72%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Nataliya Agafonova, M.D.
Dr. Nataliya Agafonova, M.D.
Chief Medical Officer
Chief Medical Officer
60.64K
+47.17%
Dr. Nataliya Agafonova, M.D.
Dr. Nataliya Agafonova, M.D.
Chief Medical Officer
Chief Medical Officer
60.64K
+47.17%
Dr. Nataliya Agafonova, M.D.
Dr. Nataliya Agafonova, M.D.
Chief Medical Officer
Chief Medical Officer
60.64K
+47.17%
Mr. Stephen H. (Steve) Willard, Esq.
Mr. Stephen H. (Steve) Willard, Esq.
Chief Executive Officer
Chief Executive Officer
58.42K
-3.09%
Mr. Stephen H. (Steve) Willard, Esq.
Mr. Stephen H. (Steve) Willard, Esq.
Chief Executive Officer
Chief Executive Officer
58.42K
-3.09%
Mr. Stephen H. (Steve) Willard, Esq.
Mr. Stephen H. (Steve) Willard, Esq.
Chief Executive Officer
Chief Executive Officer
58.42K
-3.09%
FAQs
Who are the top five shareholders of Longeveron Inc?
The top five shareholders of Longeveron Inc are: Dr. Nataliya Agafonova, M.D.
How many institutions hold shares of Longeveron Inc (LGVN)?
As of 2026Q1, 62 institutions hold shares of Longeveron Inc, with a combined market value of approximately 2.25M, accounting for 8.08% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 1131825.00.